BioSpace News Archive

Business

Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2022

Qilian International Holding Group Limited, a China-based pharmaceutical and chemical products manufacturer, announced its unaudited financial results for the first six months of fiscal year 2022 ended March 31, 2022.

September 30, 2022
·
12 min read
Business

Stealth BioTherapeutics Announces Departure of Chief Financial Officer

Stealth BioTherapeutics Corp announced that Robert Weiskopf, Stealth’s chief financial officer, is leaving the company effective September 30, 2022.

September 30, 2022
·
5 min read
Drug Development

Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

Apellis Pharmaceuticals, Inc. announced new data from the 24-month Phase 3 OAKS study of pegcetacoplan, an investigational targeted C3 therapy, for the treatment of geographic atrophy secondary to age-related macular degeneration.

September 30, 2022
·
9 min read
Biotech Bay

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 01, 2022

Adicet Bio, Inc. announced it granted inducement awards on September 30, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to four individuals hired by Adicet in September 2022.

September 30, 2022
·
2 min read
Pharm Country

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

Aptorum Group Limited provided a business update and announced financial results for the six months ended June 30, 2022.

September 30, 2022
·
11 min read
Business

Skanska builds ambulatory care cancer center in Livingston, New Jersey, USA, for USD 58M, about SEK 570M

Skanska has signed a contract with RWJBarnabas Health to build an ambulatory care cancer center in Livingston, New Jersey, USA.

September 30, 2022
·
1 min read
Drug Development

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Rocket Pharmaceuticals, Inc. announces positive clinical updates from its Phase 1 Danon Disease Trial for RP-A501 through an oral poster session at the Heart Failure Society of America Annual Scientific Meeting 2022.

September 30, 2022
·
14 min read
Drug Development

Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)

Zealand Pharma A/S announced positive topline results from the pivotal Phase 3 trial of glepaglutide, a long-acting GLP-2 analogue designed for once or twice weekly subcutaneous delivery via auto-injector, in patients with short bowel syndrome.

September 30, 2022
·
9 min read
Genetown

KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership Workshop

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2022 HAE International Global Leadership Workshop taking place in Frankfurt, Germany from October 6-9.

September 30, 2022
·
4 min read
Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

Pharvaris, a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, announced the promotion of Annick Deschoolmeester to Chief Human Resources Officer.

September 30, 2022
·
5 min read